Immucell CORP /DE/ 8-K filings

ImmuCell Corporation announced preliminary unaudited sales results for Q2 2026, showing an 11.5% increase in total product sales compared to Q2 2025, driven by significant domestic sales growth.

ImmuCell Corporation announced the results of its 2026 Annual Meeting of Stockholders, where all proposals, including director elections and compensation plans, were approved.

ImmuCell Corporation announces a $3.5 million manufacturing expansion to boost First Defense product line output, starting immediately.

ImmuCell Corporation announced preliminary unaudited sales results for Q1 2026, showing a significant 28.4% increase in total product sales compared to the prior year.

ImmuCell Corporation announced the appointment of Kathy Turner, a seasoned animal health executive, to its Board of Directors, effective April 1, 2026.

ImmuCell Corporation announced unaudited financial results for 2025, reporting a significant increase in net operating income and a reduced net loss, driven by improved gross margins and strategic focus on its First Defense franchise.

Two ImmuCell Corporation directors, Steven A. Rosgen and Bryan K. Gathagan, will not seek re-election at the 2026 Annual Meeting due to time constraints.

ImmuCell Corporation updates employment agreements and grants significant equity awards to its CFO, SVP of Sales & Marketing, and CEO, linking compensation to performance and retention.

ImmuCell announced preliminary Q4 2025 sales declined 1.6% to $7.6 million, while full-year 2025 sales rose 4.3% to $27.6 million, alongside a strategic pivot from Re-Tain to First Defense.

ImmuCell announced a strategic pivot to its First Defense franchise, pausing investment in Re-Tain after receiving an FDA Incomplete Letter due to contract manufacturer deficiencies.

ImmuCell Corporation announced unaudited financial results for Q3 2025, showing a significant swing to net income for the nine-month period despite a quarterly sales decrease.

ImmuCell Corporation announced the official start of its new President and CEO, Olivier te Boekhorst, alongside the expansion of its Board of Directors and new officer appointments.

ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2025, showing an 8% decrease compared to the prior year, consistent with previous guidance regarding inventory restocking.

ImmuCell Corporation announced the appointment of Olivier te Boekhorst, a seasoned animal health and diagnostics executive, as its new President and Chief Executive Officer, effective November 1, 2025.

ImmuCell Corporation secured an extension of its $1 million line of credit with Maine Community Bank until September 11, 2026.

ImmuCell Corporation announced unaudited financial results for the second quarter ended June 30, 2025, highlighting significant sales growth and a return to profitability.

ImmuCell Corporation successfully refinanced its existing bank debt, securing a new loan with Maine Community Bank at a lower interest rate and extended maturity, eliminating significant near-term balloon payments.

ImmuCell Corporation announced preliminary, unaudited product sales for the second quarter of 2025, showing significant growth across all reported periods and a substantial reduction in its order backlog.

ImmuCell Corporation has announced the commencement of a search for a new President and CEO as current leader Michael F. Brigham plans to retire by early 2026.

ImmuCell Corporation's 2025 Annual Meeting saw shareholders re-elect all directors and ratify the auditor, but reject the executive compensation program and an amendment to increase shares for the 2017 Stock Option and Incentive Plan.

ImmuCell Corporation announces an 11% increase in product sales and record net income for the first quarter of 2025.

ImmuCell Corporation announced preliminary, unaudited sales results for Q1 2025, achieving an all-time quarterly sales record of $8.1 million, a 11% increase compared to Q1 2024.

ImmuCell Corporation has appointed Timothy C. Fiori as its new Chief Financial Officer, effective April 7, 2025.

ImmuCell Corporation reports a 52% increase in product sales for both the fourth quarter and full year of 2024, along with a shift to positive EBITDA.

ImmuCell Corporation announces the settlement of an insurance claim for $426,587 related to production contamination events from late 2022 through April 2024.

ImmuCell Corporation reported a 52% increase in both fourth-quarter and full-year 2024 sales, alongside a reduction in order backlogs and progress in the regulatory approval process for Re-Tain.

ImmuCell Corporation has entered into an agreement with Vice President of Manufacturing Operations, Elizabeth L. Williams, for a part-time transition period until her retirement on July 1, 2025.

ImmuCell Corporation and Norbrook Laboratories Limited have amended their supply agreement, setting a termination date of March 31, 2026, for their collaboration on Re-Tain.

ImmuCell Corporation announced a significant 11% increase in product sales for the third quarter of 2024, alongside a 51% increase over the first nine months of the year, and is progressing towards FDA approval for its Re-Tain product.

ImmuCell reports a significant 51% increase in sales for the first nine months of 2024, alongside a substantial order backlog, while also progressing towards FDA approval for Re-Tain.